Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-25T08:09:54.075Z Has data issue: false hasContentIssue false
  • English
  • Français

Can Buspirone Induce Rebound, Dependence or Abuse?

Published online by Cambridge University Press:  06 August 2018

Malcolm Lader
Malcolm Lader*
Affiliation:
Institute of Psychiatry, De Crespigny Park, London SE5 8AF
Get access Rights & Permissions [Opens in a new window]

Abstract

Buspirone is a newer anxiolytic which differs chemically and pharmacologically from the benzodiazepines. The question as to whether buspirone can induce rebound, dependence, or abuse can be examined through a variety of clinical and control studies, as well as animal studies, together with meticulous follow-up of adverse reports. It is concluded that, on present evidence, the short-term use of buspirone is unlikely to be followed by rebound or long-term use through dependence; nor is abuse likely to be a problem.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 159 , Issue S12: Anxiety and Serotonin , September 1991 , pp. 45 - 51
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ashton, C. H., Rawlins, M. D. & Tyrer, S. P. (1990) A double-blind placebo controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. British Journal of Psychiatry, 157, 232–238.Google Scholar
Balster, R. L. & Woolverton, W. L. (1982) Intravenous buspirone self-administration in rhesus monkeys. Journal of Clinical Psychiatry, 43, 34–37.Google Scholar
Bond, A. J. & Lader, M. H. (1981) Comparative effects of diazepam and buspirone on subjective feelings, psychological tests and the EEC International Pharmacopsychiatry, 16, 212–220.CrossRefGoogle Scholar
Chouinard, G., Anne, L., Fontaine, R., et al (1983) New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 7, 669–673.Google Scholar
Cole, J. O., Orzack, M. H., Beake, B., et al (1982) Assessment of the abuse liability of buspirone in recreational sedative users. Journal of Clinical Psychiatry, 43, 69–74.Google Scholar
DuPont, R. L. (1986) Benzodiazepines: The Social Issues. Rockville, MA: Institute for Behavior and Health.Google Scholar
Fontaine, R., Beaudry, P., Beauclair, L., et al (1987) Comparison of withdrawal of buspirone and diazepam: a placebo controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 11, 189–197.Google Scholar
Griffith, J. D., Jasinski, D. R., Casten, G. P., et al (1986) Investigation of the abuse liability of buspirone in alcohol-dependent patients. American Journal of Medicine, 80, 30–36.CrossRefGoogle ScholarPubMed
Hendry, J. S., Balster, R. L. & Rosecrans, J. A. (1983) Discriminative stimulus properties of buspirone compared to central nervous system depressants in rats. Pharmacology, Biochemistry and Behavior, 19, 97–101.Google Scholar
Japanese Study (1989) Buspirone three-arm double-blind study in Japan (Tokyo, Osaka area). PRDD Statistical Report. Bristol-Myers.Google Scholar
Lader, M. (1988) β-adrenoceptor antagonists in neuropsychiatry: an update. Journal of Clinical Psychiatry, 6, 213–223.Google Scholar
Lader, M. & Olajide, D. (1987) A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology, 7, 11–15.Google Scholar
Moring, J., Alarotu, P., Haukijarvi, A., et al (1989) Buspirone vs diazepam in treatment of anxiety in general practice. In Psychiatry Today: Accomplishments and Promises, p. 266. New York: Plenum.Google Scholar
Murphy, S. M., Owen, R. & Tyrer, P. (1989) Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks’ treatment with diazepam or buspirone. British Journal of Psychiatry, 154, 529–534.Google Scholar
Nelson, R. C. (1986) Comment: addiction liability of benzodiazepines and buspirone. Drug Intelligence and Clinical Pharmacy, 20, 233–234.Google Scholar
Perry, P. J. (1985) Assessment of addiction liability of benzodiazepines and buspirone. Drug Intelligence and Clinical Pharmacy, 19, 657–658.Google Scholar
Petracca, A., Nisita, C., McNair, D., et al (1990) Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. Journal of Clinical Psychiatry, 51 (suppl. ), 31–39.Google Scholar
Petursson, H. & Lader, M. (1984) Dependence on tranquillizers. Maudsley Monograph No. 28. Oxford: Oxford University Press.Google Scholar
Power, K. G., Jerrom, D. W. A., Simpson, R. J., et al (1985) Controlled study of withdrawal symptoms and rebound anxiety after six weeks course of diazepam for generalized anxiety. British Medical Journal, 290, 1246–1248.Google Scholar
Riblet, L. A., Taylor, D. P., Eison, M. S., et al (1982) Pharmacology and neurochemistry of buspirone. Journal of Clinical Psychiatry, 43, 11–16.Google Scholar
Rickels, K. R., Schweizer, E., Csanalosi, I., et al (1988) Long-term treatment of anxiety and risk of withdrawal: prospective companion of clorazepate and buspirone. Archives of General Psychiatry, 45, 444–450.Google Scholar
Rickels, K. R., Schweizer, E., & Case, W. G. (1989) Withdrawal problems with anti-anxiety drugs: nature and management. In Psychopharmacology of Anxiety, British Association for Psychopharmacology Monograph No. 11 (ed. Tyrer, P.), pp. 283–293. Oxford: Oxford University Press.Google Scholar
Royal College of Psychiatrists (1988) Benzodiazepines and dependence: a College statement. Bulletin of the Royal College of Psychiatrists, 12, 107–108.Google Scholar
Schneiderman, J. F., Romach, M. K., Kaplan, H. L., et al (1989) Comparative abuse liability of lorazepam, buspirone and secobarbital. Clinical Pharmacology and Therapeutics, 45, 187.Google Scholar
Schweizer, E. & Rickels, K. (1986) Failure of buspirone to manage benzodiazepine withdrawal. American Journal of Psychiatry, 143, 1590–1592.Google Scholar
Taylor, D. P., Allen, L. E., Becker, J. A., et al (1984) Changing concepts of the biochemical action of the anxioselective drug, buspirone. Drug Development Research, 4, 95–108.Google Scholar
United Nations (1977) Convention on Psychotropic Substances 1971. New York: United Nations.Google Scholar
Weissman, M. (1985) The epidemiology of anxiety disorders: rates, risks, and familial patterns. In Anxiety and the Anxiety Disorders (eds Tuma, A. H. & Maser, J. D.), pp. 275–296. Hillsdale, NJ: Lawrence Erlbaum.Google Scholar
Woods, J. H., Katz, J. L. & Winger, G. (1987) Abuse liability of benzodiazepines. Pharmacological Reviews, 39, 251–413.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.